HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HTG Molecular Diagnostics, Inc. (HTGM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

HTG Molecular Diagnostics, Inc. (HTGM) Moves to Buy: Rationale Behind the Upgrade

TUCSON, Ariz., Sept. 20, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that the Fundación Instituto Valenciano de Oncología, located in Valencia, Spain (IVO), with its partners, the Fundación Pública Andaluza Progreso y Salud (FPS) and the Centro de Investigación Biomédica en Red (CIBER), have developed a laboratory-developed test (LDT) (the MPD Test) for the assessment of breast cancer recurrence based on their use of the HTG EdgeSeq™ technology.

The Fundación Instituto Valenciano de Oncología Leverages HTG Technology for Breast Cancer Laboratory-Developed Test

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Andrew Eriksen - LifeSci Advisors John Lubniewski - President, CEO & Director Shaun McMeans - SVP, CFO, Secretary & Treasurer Conference Call Participants Richard Miller - Cantor Fitzgerald Operator Good afternoon, ladies and gentlemen, and welcome to the HTG Molecular Diagnostics, Inc. Second Quarter 2022 Earnings Call. [Operator Instructions].

HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q2 2022 Results - Earnings Call Transcript

TUCSON, Ariz., Aug. 04, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended June 30, 2022 after the market close on Thursday, August 11, 2022.

HTG Molecular Diagnostics to Announce Q2 2022 Financial Results and Host Conference Call on Thursday, August 11

TUCSON, Ariz., July 19, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will host a key opinion leader (KOL) webinar on “Drug Candidate Attrition – How to Improve Clinical Development Success and Patient Outcomes” on Wednesday, July 27, 2022 at 10:00 am Eastern Time.

HTG Molecular Diagnostics Hosting a KOL Event Addressing Drug Candidate Attrition

Singing Machine Co Inc

Blue Hat Interactive Entertainment Technology

Chicken Soup for the Soul Entertainment

Revlon

Short squeeze stocks are still hot among retail traders and we're helping them out with a list of companies to watch this week! The post REV, CSSE: The Top 5 Short Squeeze Stocks to Watch This Week appeared first on InvestorPlace.

REV, CSSE: The Top 5 Short Squeeze Stocks to Watch This Week

TUCSON, Ariz., July 18, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced it has entered into an amendment of its June 24, 2020 Loan and Security Agreement (“LSA”) with Silicon Valley Bank, the bank of the world's most innovative companies and investors.

HTG Molecular Diagnostics Announces Amendment to Senior Loan Facility

Blue Apron

Evofem Biosciences Inc

Tellurian

Short squeeze penny stocks to watch right now. The post Penny Stocks To Buy?

Penny Stocks To Buy? 4 Short Squeeze Stocks To Watch After CPI Data

Ginkgo Bioworks Holdings

Globalstar

Which penny stocks are you watching right now? The post Check These 3 Penny Stocks Out For Your Watchlist  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check These 3 Penny Stocks Out For Your Watchlist

TUCSON, Ariz., July 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, has released a second white paper (the “White Paper”), further establishing the utility of its transcriptome-informed approach to drug design and discovery utilizing its proprietary HTG EdgeSeq technology.

HTG Releases Second Whitepaper for its Transcriptome-Informed Approach to Drug Discovery

Integrated Media Technology Ltd

Low float penny stocks to watch. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 Low Float Stocks To Watch Now

Faraday Future Intelligent Electric

Tuniu Corp

Check these three penny stocks out for your watchlist The post Top Penny Stocks to Buy Today? 3 to Watch Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Buy Today? 3 to Watch Right Now

Which penny stocks are you watching right now? The post Best Penny Stocks to Buy Right Now?

Best Penny Stocks to Buy Right Now? 3 to Watch in July 2022

TUCSON, Ariz., June 29, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced the customer publication of a peer reviewed journal article featuring the HTG Transcriptome Panel (HTP) less than one year after the breakthrough product's commercial release.

Publication Highlights Potential Clinical Applications of the HTG Transcriptome Panel in Bladder Cancer

Graybug Vision

Smart for Life Inc

Alaunos Therapeutics

Vallon Pharmaceuticals

Penny stocks to watch right now. The post Best Penny Stocks For July 2022?

Best Penny Stocks For July 2022? 5 To Watch Right Now

TUCSON, Ariz., June 08, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that it will be sponsoring a keynote presentation at the 7th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference in San Diego, CA, titled “Implementing Biomarker Strategy in Clinical Trials” on June 16th at 9:05 AM PT.

HTG to Sponsor Keynote Presentation Featuring Customer Use of its HTG EdgeSeq Technology in Clinical Trials

TUCSON, Ariz., June 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced its HTG EdgeSeq technology was highlighted in multiple scientific abstracts at the 2022 American Society of Clinical Oncology (ASCO) conference held in Chicago, Illinois.

HTG Technology Featured in Multiple Scientific Abstracts Highlighting Novel Applications in Precision Medicine at ASCO 2022

TUCSON, Ariz., May 17, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate virtually in the H.C. Wainwright Global Investment Conference being held May 23-26, 2022.

HTG Molecular Diagnostics to Participate in the H.C. Wainwright Global Investment Conference

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Monique Kosse - LifeSci Advisors John Lubniewski - President, CEO & Director Shaun McMeans - SVP, CFO, Secretary & Treasurer Conference Call Participants Dipesh Patel - H.C. Wainwright Operator Thank you for standing by.

HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q1 2022 Results - Earnings Call Transcript

HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of -14.08% and 15.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

HTG Molecular Diagnostics, Inc. (HTGM) Reports Q1 Loss, Lags Revenue Estimates

Call scheduled for today, May 12, at 4:30 pm ET Call scheduled for today, May 12, at 4:30 pm ET

HTG Molecular Diagnostics Reports First Quarter 2022 Results

Christina M. Carruthers, Ph.D. Joins as Vice President of Target Strategy and Early Development Christina M. Carruthers, Ph.D. Joins as Vice President of Target Strategy and Early Development

HTG Expands Therapeutics Team

Medavail Holdings Inc

Momentus

Here's what you need to know about trading penny stocks on April 7th The post Trading Penny Stocks on April 7th? Fed News Causes Market Movement appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks on April 7th? Fed News Causes Market Movement

New Sample Preparation Harmonization Designed to Enable miRNA and mRNA Profiling Without the Need for Additional Sample New Sample Preparation Harmonization Designed to Enable miRNA and mRNA Profiling Without the Need for Additional Sample

HTG Expands Features of Proprietary HTG EdgeSeq Technology

TUCSON, Ariz., March 31, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, has released its first proof-of-approach white paper (the “White Paper”), establishing the utility of its novel approach to drug discovery utilizing its proprietary platform.

News for HTG Molecular Diagnostics Stock (HTGM)